dad: sacituzumab govetican enfortumab vedotin as a 2l therapy for muc
Published 8 months ago • 109 plays • Length 5:44Download video MP4
Download video MP3
Similar videos
-
0:52
dad trial: combining sacituzumab govitecan and ev for the treatment of bladder cancer
-
4:21
sacituzumab govitecan plus enfortumab vedotin for treatment of advanced urothelial cancer
-
4:21
sacituzumab govitecan plus enfortumab vedotin in advanced urothelial cancer
-
2:20
ev-201: enfortumab vedotin for bladder cancer
-
3:25
enfortumab vedotin with pembrolizumab for bladder cancer
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
6:01
sacituzumab govitecan given accelerated fda approval for advanced urothelial cancer
-
3:38
breakthroughs in urothelial cancer treatment at esmo 2023
-
2:09
ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
-
2:43
ev-103: ev with pembrolizumab in cisplatin-ineligible urothelial carcinoma
-
1:00
adjuvant pembrolizumab for bladder cancer
-
1:16
antibody-drug conjugates in advanced urothelial cancer: sacituzumab govitecan
-
0:46
dr. sonpavde on the need for phase 3 data with pembrolizumab or atezolizumab in bladder cancer
-
2:13
case 3: mutational patterns in bladder cancer
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
5:23
ev in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer
-
1:11
using sacituzumab govitecan and other adcs in urothelial cancers
-
1:08
dr. sonpavde on accelerated approval of erdafitinib in bladder cancer
-
1:55
meet dr. joshua tarkoff - the division of endocrinology at nicklaus children's hospital